Mode
Text Size
Log in / Sign up
N/A Completed N=211 Treatment

REASSURE AV Registry

Sudden Cardiac Death · Bradycardia
Source: ClinicalTrials.gov NCT01074034 ↗
Enrolled (actual)
211
Serious AEs
24.6%
Results posted
Jun 2017
Primary outcomePrimary: Inappropriate Shock Free Rate — 97.2 % of shock free rates

Summary

Long term follow-up to monitor safety for patients implanted with a B301 ASSURE device.

Outcome Measures

OutcomeResultp-value
PRIMARY
Inappropriate Shock Free Rate
97.2
SECONDARY
Conversion Success Rate up to Three Months Post-implant
90.9

Eligibility Criteria

Inclusion Criteria

  • The patient is willing and capable of providing informed consent at an approved clinical investigational center, and able to attend the investigational center as required by the protocol
  • Patient is implanted with an investigational B301 device as part of the REASSURE AV study

Exclusion Criteria

  • None
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01074034). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search